Compositions and Methods for Treating Vaginal Infections and Pathogenic Vaginal Biofilms

Abstract

The present invention generally relates to methods and compositions for treating pathogenic vaginal biofilms. More specifically, the invention relates to pharmaceutical compositions comprising a combination of boric acid and diethylaminetetracetic acid (EDTA) and to methods of using such compositions to treat or prevent biofilm formation associated with vaginal infections, such as bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), trichomoniasis or mixed infections.

What is claimed is: 
     
         1 . A pharmaceutical composition for treating and/or preventing a vaginal infection and/or pathogenic vaginal biofilms consisting of: a) from about 100 mg to about 1 g of boric acid; b) from about 10 mg to about 500 mg of ethylene-diamine-tetra-acetic acid (EDTA); c) optionally, one or more of a surfactant, a gelling agent, a buffer, a preservative, a detergent, an oil, an alcohol, an emulsifier, a solubilizer, a humectant, a bioadhesive, an additional therapeutically active substance, and a bioactive agent selected from the group consisting of bergamot oil, tea tree oil or other essential oils, and zinc ion; and d) a pharmaceutically acceptable carrier suitable for vaginal and/or vulvar drug administration, and wherein said pharmaceutical composition has a pH of about 3.5 to about 7.5. 
     
     
         2 . The pharmaceutical composition of  claim 1  wherein the additional therapeutically active substance is a nitroimidazole. 
     
     
         3 . The pharmaceutical composition of  claim 2  wherein the nitroimidazole is selected from the group consisting of metronidazole and tinidazole. 
     
     
         4 . The pharmaceutical composition of  claim 1  wherein said pharmaceutically acceptable carrier is selected from the group consisting of one of more of an ointment, cream, gel, tablet, capsule, ovule, suppository, solution, suspension, foam, film, liposomal composition, a vaginal ring, tampon, sponge, pillow, puff, and osmotic pump system. 
     
     
         5 . An article of manufacture comprising a packaging material and a pharmaceutical composition of  claim 1  within said packaging material.